BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum

About this update from Biomark Diagnostics, Inc.

BioMark Comprehensive Metabolomics Assay Selected as Top Canadian Innovation for the CTS Beaver Den Innovation Award Vancouver, British Columbia--(Newsfile Corp. - April 14, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that the Company has been selected as one of the top four innovators to present its liquid biopsy platform at the annual Canadian Thoracic Society (CTS) Research Forum. The presentation will take place in front of a panel of experts on Wednesday, April 15, 2026, at the Calgary TELUS Convention Centre in Calgary, Alberta. The Beaver Den Innovation Award celebrates entrepreneurial spirit and groundbreaking advancements in respiratory research. The award's primary objective is to accelerate Canada's respiratory medicine agenda by investing in innovations that address respiratory illness and improve the quality of life for patients. The CTS is proud to host this competition to support researchers and start-ups dedicated to transformative commercial, social, or medical solutions. BioMark's featured project, titled "Accessible Early Lung Cancer Detection: A Home-Based AI-Enhanced Blood Test for Remote and At-Risk Populations" represents a key milestone in the Company's strategy. By leveraging metabolomics and machine learning to analyze small blood samples, BioMark aims to move beyond traditional hospital-centric screening. This initiative focuses on expanding access to underserved communities, including rural, northern, and Indigenous populations that currently face significant barriers to lung cancer screening. "The opportunity to present our work to a panel of respiratory experts at the Beaver Den Innovation Award is a significant honor for BioMark," said Rashid Ahmed Bux, President and CEO. "It provides critical third-party validation of our investments in metabolomics and machine learning models that accurately classify cancer-specific metabolic signatures. Our mission is to transition from hospital-dependent screening to a decentralized, home-based model, ensuring that all Canadians, regardless of geography, have access to early detection." Lung cancer remains the leading cause of cancer-related deaths in Canada,...

View stock analysis, news, and events for Biomark Diagnostics, Inc.